Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Equity Average (2016 - 2026)

Lexaria Bioscience's Equity Average history spans 11 years, with the latest figure at $5.4 million for Q1 2026.

  • Quarterly results put Equity Average at $5.4 million for Q1 2026, down 33.56% from a year ago — trailing twelve months through Feb 2026 was $5.4 million (down 33.56% YoY), and the annual figure for FY2025 was $5.1 million, down 0.75%.
  • Equity Average for Q1 2026 was $5.4 million at Lexaria Bioscience, up from $3.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $11.3 million in Q1 2022 to a low of $3.0 million in Q4 2023.
  • The 5-year median for Equity Average is $6.0 million (2025), against an average of $6.5 million.
  • The sharpest move saw Equity Average surged 181.74% in 2024, then tumbled 58.21% in 2025.
  • Year by year, Equity Average stood at $6.8 million in 2022, then plummeted by 55.38% to $3.0 million in 2023, then skyrocketed by 181.74% to $8.5 million in 2024, then tumbled by 58.21% to $3.6 million in 2025, then surged by 50.62% to $5.4 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $5.4 million, $3.6 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.